1. Lee M.V., Katabathina V.S., Bowerson M.L., Mityul M.I., Shetty A.S., Elsayes K.M., Balachandran A., Bhosale P.R., McCullough A.E., Menias C.O. BRCA-associated Cancers: Role of Imaging in Screening, Diagnosis, and Management. Radiographics. 2017; 37(4): 1005-23. https://doi.org/10.1148/rg.2017160144.
2. Human Genome Variation Society [Internet]. [cited 2019 Sep 30]. URL: https://www.hgvs.org.
3. Huang Y.W. Association of BRCA1/2 mutations with ovarian cancer prognosis: An updated meta-analysis. Medicine (Baltimore). 2018; 97(2): 9380. https://doi.org/10.1097/MD.0000000000009380.
4. Tung N.M., Garber J.E. BRCA1/2 testing: therapeutic implications for breast cancer management. Br J Cancer. 2018; 119(2): 141-52. https://doi.org/10.1038/s41416-018-0127-5.
5. Dalton H.J., Coleman R.L. New biologic frontiers in ovarian cancer: Olaparib and PARP inhibition. Am J Hematol Oncol. 2015; 11(5): 5-12.
6. Kechin A.A., Boyarskikh U.A., Ermolenko N.A., Tyulyandina A.S., Lazareva D.G., Avdalyan A.M., Tyulyandin S.A., Kushlinskii N.E., Filipenko M.L. Loss of Heterozygosity in BRCA1 and BRCA2 Genes in Patients with Ovarian Cancer and Probability of Its Use for Clinical Classification of Variations. Bull Exp Biol Med. 2018; 165(1): 94-100. https://doi.org/10.1007/s10517-018-4107-9.
7. Hamel N., Feng B.J., Foretova L., Stoppa-Lyonnet D., Narod S.A., Imyanitov E., Sinilnikova O., Tihomirova L., Lubinski J., Gronwald J., Gorski B., Hansen Tv., Nielsen F.C., Thomassen M., Yannoukakos D., Konstantopoulou I., Zajac V., Ciernikova S., Couch F.J., Greenwood C.M., Goldgar D.E., Foulkes W.D. On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations. Eur J Hum Genet. 2011; 19(3): 300-6. https://doi.org/10.1038/ejhg.2010.203.
8. Huang K.L., Liu Y.L., Hsu Y.Y., Kuo W.L. Retrospective Analysis of Clinicopathological Features and Familial Cancer History of Synchronous Bilateral Breast Cancer. Healthcare (Basel). 2021; 9(9): 1203. https://doi.org/10.3390/healthcare9091203.
9. Bateneva E.I., Meshcheryakov A.A., Krokhina O.V., Petrovskii A.V., Ragimov A.A., Kadochnikova V.V., Trofimov D.Yu., Lyubchenko L.N. Odnonukleotidnye polimorfizmy: rol' v razvitii raka molochnoi zhelezy i perspektivy klinicheskogo primeneniya. Malignant Tumours 2015; 2: 3-12. https://doi.org/10.18027/2224-5057-2015-2-3-12.
10. Underhill C., Toulmonde M., Bonnefoi H. A review of PARP inhibitors: from bench to bedside. Ann Oncol. 2011; 22(2): 268-79. https://doi.org/10.1093/annonc/mdq322.
11. Anastasia P.J. Olaparib in Epithelial Ovarian Cancer. J Adv Pract Oncol. 2016; 7(7): 756-61.
12. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., Santarosa M., Dillon K.J., Hickson I., Knights C., Martin N.M., Jackson S.P., Smith G.C., Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434(7035): 917-21. https://doi.org/10.1038/nature03445.
13. Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., Kyle S., Meuth M., Curtin N.J., Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005; 434(7035): 913-7. https://doi.org/10.1038/nature03443. Erratum in: Nature. 2007; 447(7142): 346.
14. Evers B., Drost R., Schut E., de Bruin M., van der Burg E., Derksen P.W., Holstege H., Liu X., van Drunen E., Beverloo H.B., Smith G.C., Martin N.M., Lau A., O’Connor M.J., Jonkers J. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res. 2008; 14(12): 3916-25. https://doi.org/10.1158/1078-0432.CCR-07-4953.
15. Tyulyandin S.A., Kolomiets L.A., Morkhov K.Yu., Nechushkina V.M., Pokataev I.A., Rumyantsev A.A., Tyulyandina A.S., Urmancheeva A.F., Khokhlova S.V. Prakticheskie rekomendatsii po lekarstvennomu lecheniyu raka yaichnikov, pervichnogo raka bryushiny i raka matochnykh trub. Zlokachestvennye opukholi: Prakticheskie rekomendatsii RUSSCO. 2021; 11(3s2): 164-76. https://doi.org/10.18027/2224-5057-202111-3s2-10.
16. Tyulyandina A., Kekeeva T., Karaseva V., Gorbunova V., Kolomiets L., Filipenko M., Demidova I., Lyubchenko L., Imianitov E., Cherdyntseva N., Moliaka Y., Vodolazhky D., Andreev S., Statsenko G., Saevets V., Khokhlova S., Tkachenko S., Koroleva I., Lisyanskaya A., Tjulandin S. Comprehensive analysis of germline and somatic BRCA1/2 mutations in ovarian cancer population: Interim analysis of OVATAR prospective study. J. Clin. Oncol. 2017. 35(15).
17. Tyulyandina A., Harrison D., Yin W., Stepanova E., Kochenkov D., Solomko E., Peretolchina N., Daeyaert F., Joos J.B., Van Aken K., Byakhov M., Gavrilova E., Tjulandin S., Tsimafeyeu I. Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies. Investigational new drugs. 2017; 35(2): 127-133. https://doi.org/10.1007/s10637-016-0404-1.
18. Banerjee S., Moore K.N., Colombo N., Scambia G., Kim B.G., Oaknin A., Friedlander M., Lisyanskaya A., Floquet A., Leary A., Sonke G.S., Gourley C., Oza A., González-Martín A., Aghajanian C., Bradley W.H., Holmes E., Lowe E.S., DiSilvestro P. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021; 22(12): 1721-31. https://doi.org/10.1016/S1470-2045(21)00531-3. Erratum in: Lancet Oncol. 2021; 22(12): 539.
19. Poveda A., Floquet A., Ledermann J.A., Asher R., Penson R.T., Oza A.M., Korach J., Huzarski T., Pignata S., Friedlander M., Baldoni A., Park-Simon T.W., Tamura K., Sonke G.S., Lisyanskaya A., Kim J.H., Filho E.A., Milenkova T., Lowe E.S., Rowe P., Vergote I., Pujade-Lauraine E.; SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a doubleblind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2021; 22(5): 620-31. https://doi.org/10.1016/S1470-2045(21)00073-5.
20. Kaufman B., Shapira-Frommer R., Schmutzler R.K., Audeh M.W., Friedlander M., Balmaña J., Mitchell G., Fried G., Stemmer S.M., Hubert A., Rosengarten O., Steiner M., Loman N., Bowen K., Fielding A., Domchek S.M. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015; 33(3): 244-50. https://doi.org/10.1200/ JCO.2014.56.2728.
21. Audeh M.W., Carmichael J., Penson R.T., Friedlander M., Powell B., Bell-McGuinn K.M., Scott C., Weitzel J.N., Oaknin A., Loman N., Lu K., Schmutzler R.K., Matulonis U., Wickens M., Tutt A. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010; 376(9737): 245-51. https://doi.org/10.1016/S0140-6736(10)60893-8.